Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells
/in Breast Cancer, Dendritic Cells, International Publications /von 2003-02-15 / J. Immunol. 2003 Feb;170(4):1980-6A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer
/in Hepatocellular Carcinoma, International Publications /von 2003-02-06 / Cancer Immunol. Immunother. 2003 Mar;52(3):155-61HER2 dendritic cell vaccines
/in Breast Cancer, Dendritic Cells, International Publications /von 2003-02-01 / Clin Breast Cancer 2003 Feb;3 Suppl 4:S164-72Fusions of breast cancer and dendritic cells as a novel cancer vaccine
/in Breast Cancer, Dendritic Cells, International Publications /von 2003-02-01 / Clin. Breast Cancer 2003 Feb;3 Suppl 4:S158-63Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease
/in International Publications, Malignant Melanoma /von 2003-02-01 / J Dtsch Dermatol Ges 2003 Feb;1(2):120-5Dendritic cell therapy of cancer: can it fulfill its promise?
/in Dendritic Cells, International Publications /von 2003-02-01 / Expert Rev Anticancer Ther 2003 Feb;3(1):1-3
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution